If you do enough interviews you are bound to get a few great ones. Often when we talk to researchers they either hold back on information that they are afraid to share or they try to be experts on everything we ask them. Our publisher, Steve Freed, had a chance to chat with Dr. David D’Alessio, Associate Professor of Medicine, Division of Endocrinology, University of Cincinnati, about GLP-1-like compounds, beta cells and glucose toxicity. Dr. D’Alessio presented research on these topics at the recent ADA Scientific Sessions — his information was eye-opening to say the least and may help explain why some of our patients have problems no matter what we try.
Our Survey Analysis continues this week with a close look at our readers’ prescribing habits and reasons for choosing GLP-1 analogs. And this week our Case Study focuses on the selection of a GLP-1 analog for improving glucose levels.